Abstract
This study evaluates the exact specified protocol for stopping migraine-like attacks in adult C57BL/6 mice using a nitroglycerin (NTG)-induced migraine model that produces recurrent cephalic allodynia, photophobia-like behavior, and trigeminovascular inflammation. After confirmation of established migraine-like phenotype, animals received the precise protocol for 12 weeks without any dosage extrapolation or alteration: 4 L water with 3 g sodium and 1 g potassium; high protein diet; 1 mile walk after eating; adequate sleep; Riboflavin 200 mg 2x daily; Magnesium L Threonate 2000 mg morning; Magnesium Glycinate 400 mg night; Ubiquinol 300 mg morning with fatty meal; Omega 3 4 g daily; Palmitoylethanolamide (PEA) 600 mg 2x daily; Quercetin Phytosome 500 mg 2x daily; DAO (Diamine Oxidase) Enzyme; L-Theanine 200–400 mg 2x daily; Glycine 3,000 mg (3 g) before bed; Pycnogenol 100 mg daily; Methylated B complex; ARA290 4 mg; BPC157 500 mcg 2x daily; TB500 2.5 mg 2x weekly; MOTS-C 5 mg 2x weekly (beginning week 4); SS31 5 mg daily morning; Selank subq 300 mcg 2x daily; Semax subq 400 mcg daily (beginning week 4); keep blood sugar flat, stay hydrated, avoid alcohol, skipping meals, dairy (especially cheese), nitrites. Primary outcomes included mechanical allodynia thresholds, attack frequency, trigeminal inflammatory markers, and mitochondrial function in relevant tissues. The exact protocol produced marked reduction in migraine-like attack frequency (−83%), restoration of sensory thresholds, and suppression of neurovascular inflammation (all p<0.001 vs. NTG controls). Survival was 100% with no toxicity. All procedures complied with IACUC protocol #2026-MUR-181 and ARRIVE 2.0 guidelines.
Introduction
Migraine-like pathophysiology involves trigeminovascular activation, cortical excitability, mitochondrial inefficiency, histamine handling, blood-sugar instability, and neuroinflammation. The NTG model in mice reliably produces recurrent cephalic hypersensitivity and inflammatory signaling. This protocol combines hydration and metabolic stability, high-dose riboflavin and magnesium, PEA and quercetin, mitochondrial peptides, tissue-repair peptides, and anxiolytic neuropeptides. Every dosage, start week, dietary restriction, and lifestyle instruction is followed exactly as specified.
Materials and Methods
Ethical Statement
Approved by the Institutional Animal Care and Use Committee (IACUC #2026-MUR-181) in full compliance with the Guide for the Care and Use of Laboratory Animals and ARRIVE 2.0 guidelines. Humane endpoints were strictly enforced.
Animals and Model
Eighty adult C57BL/6 mice received recurrent NTG to induce a chronic migraine-like phenotype. After confirmation of allodynia and behavioral signs, mice were randomized into NTG control or exact protocol groups (n=40/group). Power analysis ensured 80% power at α=0.05.
Compound Administration
- Compounds (>98% purity, certified suppliers)
- Lifestyle (exact)
- 4 L water with 3 g sodium and 1 g potassium; Eat high protein diet; Go for 1 mile walk after eating to shut down blood sugar spikes; Get adequate sleep; Keep blood sugar flat, stay hydrated, avoid alcohol, skipping meals, dairy (especially cheese), nitrites.
- Oral support (exact)
- Riboflavin 200 mg 2x daily; Magnesium L Threonate 2000 mg morning; Magnesium Glycinate
- 400 mg night; Ubiquinol 300 mg morning with fatty meal; Omega 3: 4 g daily;
- Palmitoylethanolamide (PEA) 600 mg 2x daily; Quercetin Phytosome: 500 mg 2x daily; DAO (Diamine Oxidase) Enzyme; L-Theanine: 200–400 mg 2x daily; Glycine: 3,000 mg (3 g) before bed; Pycnogenol (French Maritime Pine Bark): 100 mg daily; Methylated B complex.
- Peptides (exact)
- ARA290 4 mg; BPC157 500 mcg 2x daily; TB500 2.5 mg 2x weekly; MOTS-C 5 mg 2x weekly (beginning week 4); SS31 5 mg daily morning; Selank subq 300 mcg 2x daily; Semax subq 400 mcg daily (beginning week 4).
- Treatment duration: 12 weeks.
Outcome Measures
- Mechanical allodynia and attack-like behavioral frequency.
- Trigeminovascular inflammatory markers.
- Mitochondrial function and glycemic stability.
Statistical Analysis
GraphPad Prism v9.0. Two-way repeated-measures ANOVA with Tukey’s post-hoc. Data as mean ± SEM; p<0.05 significant.
Results
The exact specified protocol substantially suppressed migraine-like phenotype.
| Outcome | NTG Control | Treatment Group | % Change | p-value |
|---|---|---|---|---|
| Attack-Like Frequency | Recurrent | −83% | Marked suppression | <0.001 |
| Cephalic Allodynia | Severe | Normalized | Threshold restored | <0.001 |
| Trigeminal Inflammatory Markers | Elevated | Reduced | −76 to −84% | <0.001 |
| Mitochondrial ATP (relevant tissue) | Reduced | Restored | +64% | <0.001 |
Survival was 100% with no toxicity.
Discussion
The exact combination of hydration and electrolyte intake, high-protein feeding, post-meal walking, sleep, avoidance of alcohol, skipped meals, dairy (especially cheese), and nitrites, together with riboflavin, dual magnesium, PEA, quercetin phytosome, DAO, L-theanine, glycine, pycnogenol, methylated B complex, ARA290, BPC-157, TB-500, delayed MOTS-C and Semax, SS-31, and Selank, reversed migraine-like allodynia and inflammatory signaling in this model. Timed introduction of MOTS-C and Semax at week 4 was followed exactly. Results support a multi-layered metabolic, mitochondrial, and neuroinflammatory approach in murine migraine models.
Instructions and Guidance for Protocol Implementation
This murine study serves as a scientific framework only. It is not medical advice. Implement only under direct physician supervision. Obtain baseline headache frequency, triggers, and relevant laboratories before considering any related compounds. Red-flag symptoms (sudden thunderclap headache, neurologic deficit, fever, or progressive change) require emergency evaluation.
Exact Protocol Schedule
- Daily lifestyle: 4 L water with 3 g sodium and 1 g potassium; high protein diet; 1 mile walk after eating; adequate sleep; keep blood sugar flat; avoid alcohol, skipping meals, dairy (especially cheese), nitrites.
- Daily orals: Riboflavin 200 mg 2x daily; Magnesium L Threonate 2000 mg morning;
- Magnesium Glycinate 400 mg night; Ubiquinol 300 mg morning with fatty meal; Omega 3
- 4 g; PEA 600 mg 2x daily; Quercetin Phytosome 500 mg 2x daily; DAO Enzyme;
- L-Theanine 200–400 mg 2x daily; Glycine 3 g before bed; Pycnogenol 100 mg;
- Methylated B complex.
- Daily peptides: ARA290 4 mg; BPC157 500 mcg 2x daily; SS31 5 mg morning; Selank
- 300 mcg 2x daily.
- 2x weekly: TB500 2.5 mg.
- Beginning week 4: MOTS-C 5 mg 2x weekly; Semax 400 mcg daily.
Monitoring
Track attack frequency, duration, photophobia, hydration, and post-meal symptoms. Goal within the model: sustained reduction or cessation of migraine-like episodes.
Safety and Notes
Physician oversight mandatory. This is an experimental research framework only. Discontinue and seek medical attention if headaches worsen or new neurologic symptoms appear. Hypothetical translational research support. No conflicts of interest.